1. Introduction {#sec1}
===============

Serum *α*-fetoprotein (AFP) has been proposed as a tumor marker for screening liver tumor and germ cell tumors in the clinic \[[@B1]--[@B3]\]. 70--95% of hepatocellular cancers are associated with increased AFP level. Serum AFP-elevated gastric cancer was first reported by Alpert et al. in 1970 \[[@B4]\]. Many other reports followed. The incidence of AFP-producing gastric cancer was merely 1.3--15.0% worldwide \[[@B5]\]. In most literatures, the gastric cancer patients with serum AFP elevation were found to have doughty invasiveness and poor prognosis \[[@B6]--[@B9]\]. Also, Liu et al. reported that the dismal prognosis of serum AFP-elevated gastric cancer was mainly due to high incidence of synchronous and metachronous liver metastasis, even when radical operation was done \[[@B5]\]. Therefore, systemic chemotherapy became the predominant treatment method for serum AFP-elevated gastric cancer with liver metastasis (GCLM).

Due to the rarity of this special cancer, there is limited data in the literature about optimal treatment modality. Although previous studies reported that conventional chemotherapy was predominantly ineffective for these patients \[[@B10], [@B11]\], it remains controversial whether to perform systemic chemotherapy for this subtype of GCLM, and there had been so far no suggestion for choosing the optimal regimen.

The potential underlying molecular mechanism of AFP-producing gastric cancer may be the common embryonic origin of the stomach and liver from the foregut \[[@B12]\]. Koide et al. found that AFP-related gastric cancers had higher proliferative activity, weaker apoptosis, and richer neovascularization, compared with that of AFP-negative gastric cancers \[[@B13]\]. As the precise underlying mechanism of serum AFP-elevated GC remains to be elucidated, the optimal treatment approach requires further consideration. We aim to discover the optimal treatment modality for this special subtype GCLM.

2. Patients and Methods {#sec2}
=======================

2.1. Patient Selection {#sec2.1}
----------------------

Between 2005 and 2016, 2047 patients were diagnosed with advanced gastric adenocarcinoma in our institute. 516 of them were diagnosed with liver metastasis (LM), including postoperative LM and LM at the initial diagnosis. We included subjects who had serum AFP test result before treatment, leaving 319 patients for analysis. Pretreatment serum AFP was assessed by radioimmunoassay (normal value: \<7.0 ng/ml).

2.2. Data Collection {#sec2.2}
--------------------

We collected age, gender, ECOG, primary lesion site, histological type, Lauren classification, human epidermal growth factor receptor-2 (HER2) status, serum AFP level before treatment, first-line chemotherapy regimens, response, local treatment for LM, and survival information.

2.3. Follow-Up Care {#sec2.3}
-------------------

All patients were regularly followed up from the date of the first hospitalization at our center. Objective response rate (ORR) were evaluated by RECIST version 1.0 (before 2009) and RECIST version 1.1, and severe adverse events (≥grade 3) were recorded. Overall survival (OS) was defined as the time from inspection of liver metastasis to death from any cause or last follow-up.

2.4. Statistics {#sec2.4}
---------------

The Pearson chi-square test was used to measure the differences between variables. The Fisher exact test was used when the numbers were less than five. To identify prognostic factors of overall GCLM patients and the AFP ≥ 20 ng/ml subgroup, survival durations were calculated using the Kaplan-Meier method and Cox regression. For all tests, a *P* value \< 0.05 was defined as significant. The SPSS software program (version 21.0; SPSS, Chicago, Illinois) was used for the analyses. The GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA) was used for chart making.

3. Results {#sec3}
==========

3.1. Characteristics of GCLM of the AFP ≥ 20 ng/ml Group and AFP \< 20 ng/ml Group {#sec3.1}
----------------------------------------------------------------------------------

Of the 319 eligible patients, 74 (23.2%) were found to have serum AFP ≥ 20 ng/ml. [Table 1](#tab1){ref-type="table"} compared the clinicopathologic features of patients between the AFP ≥ 20 ng/ml group (*n* = 74) and AFP \< 20 ng/ml group (*n* = 245). Results of age, gender, ECOG, disease status, primary lesion site, Lauren classification, HER2 status, peritoneal metastasis, and number of LM were similar between two groups.

Notably, compared with the serum AFP \< 20 ng/ml group, 10 (13.5%) patients were diagnosed with hepatoid adenocarcinoma in the AFP ≥ 20 ng/ml group. Gastric hepatoid adenocarcinoma (GHA) was defined as a special subtype of primary gastric adenocarcinoma characterized by the histologic structures of "hepatocellular carcinoma- (HCC-) like differentiation" with or without excessive production of AFP \[[@B14], [@B15]\].

In addition, portal vein tumor thrombus (PVTT) occurred frequently in the AFP ≥ 20 ng/ml group, while it is rarely observed in the AFP \< 20 ng/ml group (14.9% versus 2.0%, *P* \< 0.001). The clinicopathologic features of the two groups were detailed in [Table 1](#tab1){ref-type="table"}.

3.2. Treatment Modality and Response to First-Line Chemotherapy between GCLM of the AFP ≥ 20 ng/ml Group and AFP \< 20 ng/ml Group {#sec3.2}
----------------------------------------------------------------------------------------------------------------------------------

In the analysis of first-line chemotherapy regimens, for the AFP ≥ 20 ng/ml group, 46 (62.2%) received platinum-based doublet regimen, including oxaliplatin + capecitabine in 23 patients, oxaliplatin + S-1 in 8 patients, cisplatin + capecitabine in 9 patients, cisplatin + S-1 in 2 patients, oxaliplatin + 5-FU in 3 patients, and cisplatin + 5-FU in 1 patient. 13 (17.6%) received taxane-based doublet regimen, including paclitaxel + capecitabine in 10 patients, paclitaxel + S-1 in 1 patient, paclitaxel + 5-FU in 1 patient, and docetaxel + capecitabine in 1 patient. 9 (12.2%) received triplet regimen (specific regimens were shown in [Table 5](#tab5){ref-type="table"}), and 6 (8.1%) received single-drug regimen (including paclitaxel, S-1, and capecitabine).

For the AFP \< 20 ng/ml group, 156 (63.7%) received platinum-based doublet regimen, including oxaliplatin + capecitabine in 68 patients, oxaliplatin + S-1 in 30 patients, cisplatin + capecitabine in 41 patients, cisplatin + S-1 in 5 patients, oxaliplatin + 5-FU in 8 patients, and cisplatin + 5-FU in 4 patients. 44 (18.0%) received taxane-based doublet regimen, including paclitaxel + capecitabine in 28 patients, paclitaxel + S-1 in 10 patients, paclitaxel + oxaliplatin in 2 patients, docetaxel + 5-FU in 1 patient, and docetaxel + oxaplitatin in 3 patients. Also, there were 17 (6.9%) patients who received triplet regimen (combination of platinum, taxanes, and fluorouracil drugs), and 19 (7.8%) received single-drug regimen (including paclitaxel, S-1, and capecitabine). Analysis showed no significant differences between two groups.

Among the original 319 patients, there were 68 (93.2%) and 189 (77.1%) patients evaluable for their response to first-line chemotherapy in the two groups, respectively. Compared with the AFP \< 20 ng/ml group, overall objective response rate (ORR) to first-line chemotherapy was significantly lower in the AFP ≥ 20 ng/ml group (41.2% versus 56.1%, *P* = 0.024).

With regard to second-line chemotherapy, there were fewer patients of the AFP ≥ 20 ng/ml group who received second-line chemotherapy than the AFP \< 20 ng/ml group (40.0% versus 53.0%, *P* = 0.055). Regimens mainly involved taxanes and fluorouracil. Moreover, there were 1 (1.4%) and 8 (3.3%) patients who received surgery treatment after first-line chemotherapy in the two groups. In addition, 23 (31.1%) and 60 (24.5%) patients received local treatment for LM in the two groups, respectively, and there were no significant differences between them, either. Comparison of treatments and response between two groups were shown in [Table 2](#tab2){ref-type="table"}.

3.3. Objective Response Rate (ORR) of Doublet and Triplet Regimens between the AFP ≥ 20 ng/ml Group and AFP \< 20 ng/ml Group {#sec3.3}
-----------------------------------------------------------------------------------------------------------------------------

[Table 3](#tab3){ref-type="table"} summarized the response to doublet and triplet regimen between two groups. Result showed that compared with the AFP \< 20 ng/ml group, the AFP ≥ 20 ng/ml group had a significantly poor response to platinum/taxane-based doublet regimen (38.2% versus 56.9%, *P* = 0.013). However, with chemotherapy of triplet regimen, ORR was similar between two groups (66.7% versus 66.7%, *P* = 0.676).

We further compared ORR and occurrence of severe adverse events of different regimens in the AFP ≥ 20 ng/ml group in [Table 4](#tab4){ref-type="table"}. Result showed that ORR of triplet regimen was higher than doublet regimen (66.7% versus 25.0--43.9%), but analysis showed no significance (*P* = 0.162). Notably, ORR of taxane-based doublet regimen was especially low (25.0%) .

In the analysis of adverse events, triplet regimen showed a significantly higher rate of ≥grade3 adverse events (66.7% versus 22.0--25.0%, *P* = 0.014).

3.4. Case by Case Analysis of Nine GCLM Patients with AFP ≥ 20 ng/ml Who Received Triplet Regimen as First-Line Chemotherapy {#sec3.4}
----------------------------------------------------------------------------------------------------------------------------

In the AFP ≥ 20 ng/ml group, nine patients received triplet regimen as first-line chemotherapy. Among them, six were male, and only one patient was more than 60 years old. Serum AFP levels ranged from 22 ng/ml to 208,072 ng/ml. One patient\'s primary tumor was located at GEJ, others\' primary tumor was located at gastric body or antrum. Three patients were diagnosed with hepatoid adenocarcinoma, the six left were common adenocarcinoma. Of five cases that Lauren\'s classification and HER2 status were known, one case was with intestinal type, two with diffuse type, and two with mixed type, only one case was examined as HER2 positive.

Two-thirds of patients (6/9) achieved PR after triplet regimen as first-line chemotherapy, and two achieved SD with tumor shrinkage of 18%. Only one patient\'s disease progressed quickly after only one cycle of chemotherapy. Two-thirds of patients (6/9) suffered from ≥grade 3 adverse events, and four of them had to change treatment regimens because of intolerable toxicity. Disease-free survival (DFS) and overall survival (OS) data were also included in [Table 5](#tab5){ref-type="table"}.

3.5. Prognostic Factors of Overall GCLM and GCLM with Serum AFP ≥ 20 ng/ml {#sec3.5}
--------------------------------------------------------------------------

Median serum AFP level was 480.9 ng/ml and 3.1 ng/ml in the AFP ≥ 20 ng/ml group and AFP \< 20 ng/ml group, respectively. Median overall survival period was 10.9 m and 15.7 m in the two groups (*P* = 0.004, [Figure 1](#fig1){ref-type="fig"}). Furthermore, multivariate analysis revealed that besides typical prognostic factors of histologic type, extrahepatic unresectable advanced/metastatic sites, response to chemotherapy, and so on, elevation of serum AFP was also an independent prognostic factor for overall GCLM (details were shown in [Table 6](#tab6){ref-type="table"}).

We further investigated the prognostic factors of GCLM patients with serum AFP ≥ 20 ng/ml. While the ORR of triplet regimen was excellent in AFP-elevated GCLM, analysis showed no significant difference in survival between doublet and triplet regimens (37.6 m versus 9.9 m, *P* = 0.157) due to the rather small number (9/74, 12.2%) of patients receiving triplet regimens. In addition, for GCLM patients with serum AFP ≥ 20 ng/ml, univariate and multivariate analysis revealed that response to first-line chemotherapy was an independent prognostic factor. Patients reached PR had a better prognosis, similar to overall population, while patients evaluated as SD/PD had the worst survival prognosis (*P* \< 0.001, [Figure 2](#fig2){ref-type="fig"}). Also, survival analysis showed that combined with local treatment for LM may result in better prognosis and significant difference exist (19.2 m versus 8.4 m, *P* = 0.003) ([Figure 3](#fig3){ref-type="fig"}).

4. Discussion {#sec4}
=============

The main findings of this study are as follows: (1) serum AFP ≥ 20 ng/ml GCLM showed a poorer prognosis than the AFP \< 20 ng/ml group. (2) Doublet regimen was significantly less effective for the AFP ≥ 20 ng/ml group than in the AFP \< 20 ng/ml group. (3) Triplet regimen increased ORR compared to doublet regimen when treating serum AFP ≥ 20 ng/ml GCLM, but result showed no significance on survival.

AFP is a fetal serum protein by fetal and yolk sac cells and by some fetal gastrointestinal cells \[[@B16]\]. After birth, the level of AFP rapidly decreased. The elevation of AFP in serum of people older than one year is indicative of either HCC or yolk sac tumor. In addition, some reports showed that AFP could also be produced by other tumors, including gastric cancer, rectal cancer, pancreas cancer, gallbladder cancer, lung cancer, and bladder cancer \[[@B17]\].

In 1970, Alpert et al. first reported a case of AFP-producing GC, which refers to a type of gastric cancer that AFP is positive in the immunohistochemical staining of pathological specimen \[[@B4]\]. In 1985, Ishikura et al. proposed a new entity, hepatoid adenocarcinoma of the stomach, which showed a histologic appearance typical of HCC, including solid, trabecular, and pseudogranular structure, tumor cells were round or polygonal in shape \[[@B18]\]. In addition, Nagai et al. clarified that hepatoid adenocarcinoma of the stomach had characteristic histologic features and a poor prognosis irrespective of AFP production and should be distinguished from AFP-positive GC without hepatoid features \[[@B14]\]. However, due to focal distribution and high heterogeneity of gastric hapatoid adenocarcinoma (GHA) \[[@B9], [@B19]\], almost all GHA cases reported in previous literatures were diagnosed from postoperative specimens. On the other hand, due to aggressive behavior and high frequency of liver metastasis \[[@B8]\], most patients had lost operation opportunity at diagnosis. Thus, most of our patients\' feature was just with serum AFP elevation, with only ten patients diagnosed as GHA. The definition of AFP-producing GC varies between studies owing to difficulty in setting the cut-off value; considering liver metastasis can be a factor for mild increase in AFP level, we chose AFP ≥ 20 ng/ml as a cut-off value in this study.

Serum AFP-elevated gastric cancer is rare, only accounts for 2.3--7.1% of all gastric cancers \[[@B6], [@B20]\], but in GCLM population, our result showed that 23.2% (73/319) patients\' serum AFP exceeded 20 ng/ml. To clarify the variables associated with the poor prognosis of the AFP ≥ 20 ng/ml group, we next reviewed the data of patients and analyzed the differences between two groups. Result showed the serum AFP ≥ 20 ng/ml group had a significantly poorer response to first-line chemotherapy in comparison to the AFP \< 20 ng/ml group. Also, survival analysis revealed that response to first-line chemotherapy was significantly associated with survival prognosis, and for the AFP ≥ 20 ng/ml group, those who reached PR after first-line chemotherapy had a similar survival period as those AFP \< 20 ng/ml. These results indicate that choosing effective chemotherapy regimen may improve prognosis of serum AFP-elevated GCLM.

In general treatment of inoperable locally advanced and/or metastatic (stage IV) GC, doublet combinations of platinum and fluropyrimidines are generally used, with an overall ORR of 52.2--58.7% \[[@B21], [@B22]\]. There remains controversy regarding the utility of triplet regimes, especially in China and Japan \[[@B23]\]. Although there is considerable improvement in medicine science, serum AFP-elevated GC is found to have a poor response to chemotherapy and thus associated with a poor prognosis \[[@B24]\]; basic research indicated that AFP-producing cell lines were not sensitive to many drugs \[[@B25]\]. This clinical study further suggest that this special subtype of gastric cancer may be less sensitive to doublet regimen including platinum and fluoropyrimidines, which was in accordance with a previous study reported that for GHA, ORR and disease control rate (DCR) to palliative chemotherapy was only 7.7% (1/13) and 45.1% (6/13), respectively \[[@B24]\]. However, by comparing ORR and AEs of different regimens used in the AFP ≥ 20 ng/ml group, we found that triplet regimens combining platinum, taxanes, and fluoropyrimidines achieved a satisfactory ORR in this special subtype of GCLM. Although ≥grade 3 adverse events were reported in 66.7% patients, they were all reversible and there was no treatment-related death occurred.

Despite the excellent ORR of triplet regimen, median OS was similar in patients who received triplet regimen and doublet regimen. This phenomenon that could mainly attribute to the rate of patients who received triplet regimen was relatively low in our study (9/73), and four of nine patients were still alive until the last follow-up. On the other hand, in clinic practice, triplet regimen was always used in patients with heavy tumor burden, which may be associated with poor prognosis as well. Case by case analysis revealed there were two patients who lived longer than two years. Both of them reached PR after triplet regimen chemotherapy. One of them was examined as HER2 positive and received Herceptin treatment at second-line chemotherapy. In addition, the patient also received TACE for LM, which may also improve survival prognosis of gastric cancer with liver metastasis \[[@B11], [@B26]\]. The other case was diagnosed as GHA, who also received multiline systemic treatment, including apatinib. We noted that there were two patients complicated with PVTT, which is a special characteristic of AFP-related gastric cancer \[[@B27]\]; a high rate of PVTT in AFP-producing gastric cancer (14.9% in our study) may indicate high intendancy of vascular invasion and angiogenesis \[[@B28], [@B29]\]. It was reported that silencing AFP inhibits VEGF production in human HCC cells \[[@B30]\]. The function of apatinib, as a small molecular tyrosine kinase targeting VEGF-R2 (vascular endothelial growth factor receptor-2), is antiangiogenesis. There is another case report of targeted therapy with apatinib in a patient with advanced gastric cancer and high serum level of AFP and PFS achieved five months \[[@B31]\]. Thus, the inhibitors of VEGF or VEGFR might become potential drugs to treat this special subtype of gastric cancer. This long-time survivor in our study also received TACE for LM during treatment process.

We also showed that the only patient resistant to triplet regimen was a young female, with diffuse type Lauren classification and peritoneal metastasis and ascites, which were associated with poor prognosis and bad response to conventional systemic chemotherapy \[[@B32]\]. Furthermore, in our study, almost half of patients (cases 1, 4, 7, and 8) had to stop triplet regimen during treatment process because of intolerable adverse events; thus, severe toxicity of triplet regimen may also attribute to poor survival prognosis, and optimizing triplet regimens deserves further study.

In a word, survival analysis and the two successfully treated cases indicate that although AFP-producing gastric cancer is often advanced and complicated with liver metastasis, long-term survival can be achieved by multimodality treatment including triplet regimen chemotherapy; those had a PR response of first-line chemotherapy could get more chance to be treated.

5. Conclusions {#sec5}
==============

Serum AFP-elevated gastric cancer is a small subgroup of gastric carcinoma with high metastatic potential to the liver and poor prognosis. Multimodality treatment including aggressive chemotherapy of triplet regimen may be worthwhile to improve prognosis of serum AFP-elevated GCLM; better tolerated regimens should be investigated further in the future.

6. Shortcomings and Perspectives {#sec6}
================================

Although the retrospective nature of this study and the number of cases treated with triplet regimen were relatively small, the results could still provide some clinical value. With such rare tumors, for which large clinical trials are not feasible, it became very important to summarize clinical experience retrospectively. Not limited within GCLM, maybe triplet regimen can be tried to be used in all AFP-elevated gastric cancer in future clinical practice. Although this type of gastric cancer is rare, it deserves further studies.
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![The median OS of group 1 (AFP ≥ 20 ng/ml GCLM) and group 2 (AFP \< 20 ng/ml GCLM) was 10.9 m and 15.7 m, respectively (*P* = 0.002).](GRP2017-5080361.001){#fig1}

![The median OS of group 1 (AFP ≥ 20 ng/ml and reached PR after first-line chemotherapy), group 2 (AFP ≥ 20 ng/ml and achieved SD/PD after first-line chemotherapy), group 3 (AFP \< 20 ng/ml) was 17.6 m, 9.4 m, 17.3 m, respectively (*P* \< 0.001).](GRP2017-5080361.002){#fig2}

![In serum AFP ≥ 20 ng/ml GCLM, the median OS of group 1 (with local treatment for LM) and group 2 (without local treatment for LM) was 19.2 m and 18.3 m, respectively (*P* = 0.003).](GRP2017-5080361.003){#fig3}

###### 

Comparison of characteristics of GCLM between the AFP ≥ 20 ng/ml group and AFP \< 20 ng/ml group.

  Variable                      AFP ≥ 20 ng/ml (*n* = 74)   AFP \< 20 ng/ml (*n* = 245)   *P*
  ----------------------------- --------------------------- ----------------------------- ---------
  Gender                                                                                  
   Male                         57 (77.0%)                  198 (80.8%)                   0.288
   Female                       17 (23.0%)                  47 (19.2%)                    
  Age (years)                                                                             
   ≥65                          56 (75.7%)                  165 (67.3%)                   0.111
   \<65                         18 (24.3%)                  80 (32.7%)                    
  ECOG                                                                                    
   0-1                          66 (89.2%)                  220 (89.8%)                   0.514
   2-3                          8 (10.8%)                   25 (10.2%)                    
  Disease status                                                                          
   LM after radical resection   10 (13.5%)                  45 (18.4%)                    0.216
   LM at first diagnosis        64 (86.5%)                  200 (81.6%)                   
  Primary lesion site                                                                     
   GEJ                          24 (33.3%)                  101 (42.4%)                   0.385
   Non-GEJ                      48 (66.7%)                  137 (57.6%)                   
   Unknown                      2                           7                             
  Histological type                                                                       
   Well differentiated^a^       23 (31.5%)                  94 (39.3%)                    \<0.001
   Poorly differentiated^b^     40 (54.8%)                  145 (60.7%)                   
   GHA                          10 (13.7%)                  0 (0%)                        
   Unknown                      1                           6                             
  Lauren classification                                                                   
   Intestinal type              34 (70.8%)                  103 (65.6%)                   0.633
   Diffused type                5 (10.4%)                   25 (15.9%)                    
   Mixed type                   9 (18.8%)                   29 (18.5%)                    
   Unknown                      26                          88                            
  HER2 status                                                                             
   Positive                     13 (24.5%)                  54 (30.9%)                    0.240
   Negative                     40 (75.5%)                  121 (69.1%)                   
   Unknown                      21                          70                            
  Peritoneal metastasis                                                                   
   Yes                          9 (12.2%)                   38 (15.5%)                    0.321
   No                           65 (87.8%)                  207 (84.5%)                   
  Number of LM                                                                            
   1--3                         12 (16.2%)                  48 (20.3%)                    0.367
   \>3                          62 (83.8%)                  188 (80.7%)                   
  PVTT                                                                                    
   Yes                          11 (14.9%)                  5 (2.0%)                      \<0.001
   No                           63 (85.1%)                  240 (98.0%)                   

^a^Including well-differentiated and moderately differentiated adenocarcinoma. ^b^Including poorly differentiated and signet ring cell adenocarcinoma. GHA = gastric hepatoid adenocarcinoma; ECOG = Eastern Cooperative Oncology Group; GEJ = gastroesophageal junction; HER2 = human epidermal growth factor receptor-2; AFP = *α*-fetoprotein; LM = liver metastasis; PVTT = portal vein tumor thrombus.

###### 

Comparison of treatments and response in GCLM between the AFP ≥ 20 ng/ml group and AFP \< 20 ng/ml group.

  Variables                                         AFP ≥ 20 ng/ml   AFP \< 20 ng/ml   *P*
  ------------------------------------------------- ---------------- ----------------- -------
  First-line chemotherapy regimens                                                     
   Platinum-based doublet regimen                   46 (62.2%)       156 (63.7%)       0.325
   Taxane-based doublet regimen                     13 (17.6%)       44 (18.0%)        
   Triplet regimen                                  9 (12.2%)        17 (6.9%)         
   Single-drug regimen                              6 (8.1%)         19 (7.8%)         
   Others                                           0 (0.0%)         9 (3.7%)          
  Response of first-line chemotherapy                                                  
   PR                                               28 (41.2%)       106 (56.1%)       0.024
   SD + PD                                          40 (58.8%)       83 (43.9%)        
  Subsequent therapies after the first-line chemo                                      
   Second-line chemotherapy                                                            
    Yes                                             24 (40.0%)       97 (53.0%)        0.055
    No                                              36 (60.0%)       86 (47.0%)        
   Surgery treatment                                                                   
    Yes                                             1 (1.4%)         8 (3.3%)          0.344
    No                                              73 (98.6%)       237 (96.7%)       
  Local treatment of LM^a^                                                             
   Yes                                              23 (31.1%)       60 (24.5%)        0.163
   No                                               51 (68.9%)       185 (75.5%)       

^a^Including TACE, ablation, radiotherapy, and liver resection. PR = partial response; SD = stable disease; PD = progressive disease; TACE = transcatheter arterial chemoembolization.

###### 

Comparison of ORR of different chemotherapy regimens between two groups.

  Regimens                                AFP ≥ 20 ng/ml   AFP \< 20 ng/ml   *P*
  --------------------------------------- ---------------- ----------------- -------
  Platinum/taxane-based doublet regimen                                      
   PR                                     21 (38.2%)       91 (56.9%)        0.013
   SD + PD                                34 (61.8%)       69 (43.1%)        
  Triplet regimen                                                            
   PR                                     6 (66.7%)        8 (66.7%)         0.676
   SD + PD                                3 (33.3%)        4 (33.3%)         

###### 

ORR and severe AEs of different regimens in the AFP ≥ 20 ng/ml group.

  ORR and AEs    Platinum-based doublet regimen (*n* = 41)   Taxane-based doublet regimen (*n* = 12)   Triplet regimen (*n* = 9)   *P*
  -------------- ------------------------------------------- ----------------------------------------- --------------------------- -------
  PR             18 (43.9%)                                  3 (25.0%)                                 6 (66.7%)                   0.162
  SD + PD        23 (56.1%)                                  9 (75.0%)                                 3 (33.3%)                   
  ≥grade 3 AEs   9 (22.0%)                                   3 (25.0%)                                 6 (66.7%)                   0.014

AE = adverse event; OS = overall survival.

###### 

Case by case analysis of nine AFP ≥ 20 ng/ml GCLM received triplet regimen as first-line chemotherapy.

  Age/sex   Primary lesion site   Histological type                      Serum AFP level (ng/ml)   Lauren classification   HER2 status   PVTT   Peritoneal metastasis
  --------- --------------------- -------------------------------------- ------------------------- ----------------------- ------------- ------ -----------------------
  34/M      Body                  GHA                                    455                       Intestinal              Negative      No     No
  59/M      Antrum                GHA                                    208,072                   NK                      NK            No     No
  43/M      Body                  Poorly differentiated adenocarcinoma   7307                      NK                      NK            Yes    No
  58/M      Antrum                Poorly differentiated adenocarcinoma   113                       Mixed                   Negative      No     No
  39/F      Body                  Poorly differentiated adenocarcinoma   3042                      Diffuse                 Negative      No     Yes
  56/F      Antrum                Middle-differentiated adenocarcinoma   22                        Intestinal              Positive      No     No
  75/F      Antrum                Middle-differentiated adenocarcinoma   131                       NK                      NK            No     No
  59/M      Body                  Middle-differentiated adenocarcinoma   2108                      NK                      NK            No     No
  42/M      GEJ                   GHA                                    868                       Mixed                   Negative      Yes    No

  Regimen   Cycles   Evaluation   PFS (m)   ≥grade 3 toxicity                           Other treatments                                        OS (m)   Follow-up status
  --------- -------- ------------ --------- ------------------------------------------- ------------------------------------------------------- -------- ------------------
  PCF       4        PR           9.5       BWL                                         FOLFIRINOX; olaparib; apatinib; PD-1 antibody; TACE     22.8     Alive
  PCF       6        PR           4.2       Vomiting                                    No                                                      7.1      Dead
  POS       5        SD           6.0       No                                          No                                                      11.0     Alive
  POS       5        PR           6.2       Hematological; sensory neuropathy           Radiotherapy                                            8.0      Alive
  DCF       1        PD           0.8       No                                          No                                                      1.7      Dead
  ECF       6        PR           6.1       No                                          Herceptin; TACE                                         37.6     Dead
  DCF       4        PR           3.4       Hematological; vomiting; mucosal reaction   No                                                      10.9     Dead
  PCF       3        PR           2.6       Cardiac toxicity                            Gastrectomy                                             10.9     Dead
  POS       5        SD           5.83      Hematological                               Gastrectomy; liver resection; apatinib; PD-1 antibody   13.6     Alive

F = female; M = male; NK = not known; BWL = body weight loss; PVTT = portal vein tumor thrombus; PCF = paclitaxel + cisplatin+ 5-fluorouracil; POS = paclitaxel + oxaplatin + S-1; DCF = docetaxel + cisplatin+ 5-fluorouracil; ECF = epirubicin + cisplatin+ 5-fluorouracil.

###### 

Univariate and multivariate analysis of survival outcomes in overall GCLM and of the subgroup of serum AFP ≥ 20 ng/ml.

                                 GCLM with serum AFP ≥ 20 ng/ml (*n* = 74)   Overall GCLM (*n* = 319)                                                                               
  ------------------------------ ------------------------------------------- -------------------------- ------- --------------- ----------- ------ --------- ------- -------------- -----------
  Gender                                                                                                                                                                            
   Male                          9.9                                         0.608                                                          14.1   0.609                            
   Female                        15.1                                                                                                       14.8                                    
  Age                                                                                                                                                                               
   ≤65                           9.2                                         0.773                                                          14.8   0.379                            
   \>65                          11.3                                                                                                       14.9                                    
  ECOG                                                                                                                                                                              
   0-1                           9.2                                         0.095                                                          16.5   0.227                            
   2-3                           11.3                                                                                                       14.5                                    
  Disease status                                                                                                                                                                    
   LM after radical resection    10.4                                        0.411                                                          19.3   0.046     0.700   0.359--1.364   0.295
   LM at first diagnosis         10.9                                                                                                       14.5                                    
  Primary lesion site                                                                                                                                                               
   GEJ                           14.9                                        0.103                                                          15.2   0.600                            
   Non-GEJ                       9.4                                                                                                        14.5                                    
  Histologic classification                                                                                                                                                         
   Intestinal                    12.7                                        0.757                                                          16.1   0.021     0.558   0.370--0.840   **0.005**
   Nonintestinal                 12.0                                                                                                       11.2                                    
  HER2 status                                                                                                                                                                       
   Positive                      12.7                                        0.888                                                          17.3   0.293                            
   Negative                      15.1                                                                                                       15.2                                    
  Extrahepatic M                                                                                                                                                                    
   Present                       10.4                                        0.116                                                          14.6   0.952                            
   Absent                        12.2                                                                                                       15.5                                    
  Peritoneal M                                                                                                                                                                      
   Present                       4.6                                         \<0.001                    4.411   1.817--10.712   **0.001**   10.8   0.001     1.953   1.105--3.451   **0.021**
   Absent                        11.3                                                                                                       15.4                                    
  LM numbers                                                                                                                                                                        
   1--3                          17.6                                        0.115                                                          19.5   0.002     0.416   0.236--0.733   **0.002**
   \>3                           9.9                                                                                                        12.7                                    
  First-line chemo regimen                                                                                                                                                          
   Doublet regimen               9.9                                         0.157                                                          14.9   0.816                            
   Triplet regimen               37.6                                                                                                       17.3                                    
  Response to first-line chemo                                                                                                                                                      
   PR                            15.4                                        0.017                      0.328   0.173--0.624    **0.001**   19.2   \<0.001   0.506   0.334--0.768   **0.001**
   SD + PD                       9.4                                                                                                        11.4                                    
  Local treatment for LM                                                                                                                                                            
   Yes                           19.2                                        0.003                      0.356   0.179--0.710    **0.003**   20.8   \<0.001   0.623   0.394--0.986   **0.043**
   No                            8.4                                                                                                        12.4                                    
  Serum AFP level (ng/ml)                                                                                                                                                           
   ≥20 ng/ml                                                                                                                                10.9   0.004     1.553   1.006--2.397   **0.047**
   \<20 ng/ml                                                                                                                               15.7                                    

[^1]: Academic Editor: Haruhiko Sugimura
